TY - JOUR
T1 - Hematologic and molecular responses to generic imatinib in patients with chronic myeloid leukemia
AU - Razmkhah, Farnaz
AU - Razavi, Mohsen
AU - Zaker, Farhad
AU - Kazemi, Ahmad
AU - Negari, Shahin
AU - Rasighaemi, Parisa
AU - Kalantarmotamedi, Mojdeh
AU - Zarei, Mina
AU - Pazhakh, Vahid
PY - 2010/9
Y1 - 2010/9
N2 - Background: Imatinib mesylate is a drug used in treating chronic myeloid leukemia (CML). It induces apoptosis and inhibits cell proliferation. This study aimed to evaluate hematologic and molecular responses to Imatib (Cipla Limited, Mumbai, India) in 30 chronic phase CML patients. Methods: Physical examination, CBC test, and peripheral blood smear were performed in order to assess the hematologic response in patients. Molecular response was evaluated through quantitative assessment of BCR-ABL fusion gene expression by real-time reverse transcriptase polymerase chain reaction (RT-PCR). The correlation of molecular and hematologic responses with the patient's age and sex and also with dosage and duration of Imatib consumption was analyzed statistically. Results: Ninety percent of the patients showed some sort of hematologic response that had no significant correlation with a patient's age or sex, dosage, or duration of Imatib consumption (P>0.05). Overall, 46.7% of patients showed complete molecular response (CMR), 43.3% showed partial molecular response, and 10% showed no molecular response (NMR) to Imatib. A reverse significant correlation was noted between the type of molecular response and patient's age (P<0.05). In contrast, no significant correlation was found between the type of molecular response and patient's sex, dosage, or duration of Imatib consumption (P>0.05). Conclusion: Our study results indicate that molecular and hematologic responses to Imatib were acceptably good and therefore its efficacy is comparable to that of more expensive brands like Gleevec.
AB - Background: Imatinib mesylate is a drug used in treating chronic myeloid leukemia (CML). It induces apoptosis and inhibits cell proliferation. This study aimed to evaluate hematologic and molecular responses to Imatib (Cipla Limited, Mumbai, India) in 30 chronic phase CML patients. Methods: Physical examination, CBC test, and peripheral blood smear were performed in order to assess the hematologic response in patients. Molecular response was evaluated through quantitative assessment of BCR-ABL fusion gene expression by real-time reverse transcriptase polymerase chain reaction (RT-PCR). The correlation of molecular and hematologic responses with the patient's age and sex and also with dosage and duration of Imatib consumption was analyzed statistically. Results: Ninety percent of the patients showed some sort of hematologic response that had no significant correlation with a patient's age or sex, dosage, or duration of Imatib consumption (P>0.05). Overall, 46.7% of patients showed complete molecular response (CMR), 43.3% showed partial molecular response, and 10% showed no molecular response (NMR) to Imatib. A reverse significant correlation was noted between the type of molecular response and patient's age (P<0.05). In contrast, no significant correlation was found between the type of molecular response and patient's sex, dosage, or duration of Imatib consumption (P>0.05). Conclusion: Our study results indicate that molecular and hematologic responses to Imatib were acceptably good and therefore its efficacy is comparable to that of more expensive brands like Gleevec.
KW - Chronic myeloid leukemia
KW - Hematologic response
KW - Imatib
KW - Molecular response
UR - http://www.scopus.com/inward/record.url?scp=78349294126&partnerID=8YFLogxK
U2 - 10.1309/LMR1KA61JYKUXRDX
DO - 10.1309/LMR1KA61JYKUXRDX
M3 - Article
AN - SCOPUS:78349294126
VL - 41
SP - 547
EP - 550
JO - Laboratory Medicine
JF - Laboratory Medicine
SN - 0007-5027
IS - 9
ER -